Company Name, Ticker, Competitors, else..

Kineta Inc (KANT)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Kineta Inc 's

Name: Kineta Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

KANT Sales vs. its Competitors Q1 2025

Comparing the current results to its competitors, Kineta Inc reported Revenue increase in the 1 quarter 2025 by 0 % year on year, while most of its competitors have experienced contraction in revenues by -1.25 %, achieved in the same quarter.

• List of KANT Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Kineta Inc recorded a net loss, despite income increase by most of its competitors of 0 %

<< KANT Stock Performance Comparisons

Kineta Inc 's Comment on Competition and Industry Peers

The company recognizes the competitive environment with other firms marketing or developing treatments for the same indications as its product candidates.

<< See the full list of KANT competitors

*Market share is calculated based on total revenue.

News about Kineta Inc Contracts

Kineta’s KVA12123 Shows Promising Results in Ongoing Phase 1/2 VISTA101 Study Presented at SITC 2024

November 8, 2024
: Kineta, a biotechnology company focused on developing innovative therapies for cancer and other diseases, recently presented updated clinical results from its ongoing Phase 1/2 VISTA101 study of KVA12123 at the Society for Immunotherapy of Cancer (SITC) 2024. This article outlines the key findings from the presentation, with a focus on the safety, efficacy, and future implications of KVA12123 as a potential immunotherapy treatment. KVA12123 is an investigational drug designed to enhance the body s immune response to cancer. The Phase 1/2 VISTA101 study aims to evaluate the safety, tolerability, and preliminary efficacy of KVA12123 in patients with advanced solid tumors. The presentation at SITC 2024 pro...

KANT's Stock Performance relative to its Competitors

Publicly Traded Peers of Kineta Inc

Y mabs Therapeutics inc
Share Performance

+79.38%

This Quarter

Y mabs Therapeutics inc

Profile

Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.

More about Y mabs Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 390.188 mill.	$ 84.721 mill.	$ -22.223 mill.

Terns Pharmaceuticals Inc
Share Performance

+54.82%

This Quarter

Terns Pharmaceuticals Inc

Profile

Terns Pharmaceuticals Inc. is a biopharmaceutical company.

More about Terns Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 4,933.171 mill.	$ - mill.	$ -96.207 mill.

Syros Pharmaceuticals Inc
Share Performance

+300.00%

Over The Past 5 Days

Syros Pharmaceuticals Inc

Profile

Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.

More about Syros Pharmaceuticals Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.016 mill.	$ - mill.	$ -97.815 mill.

Supernus Pharmaceuticals inc
Share Performance

+1.80%

30 Days

Supernus Pharmaceuticals inc

Profile

Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.

More about Supernus Pharmaceuticals inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,538.222 mill.	$ 776.833 mill.	$ -29.016 mill.

Shattuck Labs Inc
Share Performance

-12.75%

30 Days

Shattuck Labs Inc

Profile

Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.

More about Shattuck Labs Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 775.541 mill.	$ - mill.	$ -49.874 mill.

133 more competitors available

Sources: Kineta Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 3, 2026 4:07 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kineta Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.